Why the Future of Dementia Research Depends on Collaboration—Not Competition
For decades, research into various neurodegenerative diseases has largely operated in silos. Alzheimer’s disease. Lewy body dementia. Huntington’s disease. Frontotemporal dementia. Parkinson’s disease. Vascular dementia. Etc.
Separate funding streams. Separate labs. Separate conversations.
But biology does not work that way and increasingly, neither should research.
What researchers are learning, at both the clinical and molecular level, is that these diseases are not as distinct as we once believed. Alzheimer’s disease and Parkinsons disease, for example, share overlapping features in how they develop and progress. Huntington’s disease and Alzheimer’s disease share cellular pathways, such as the activation of caspase-6 and the presence of brain cell inclusions. FTD and Lewy Body dementia are both proteinopathies, where abnormal proteins accumulate disrupting neuron function.
Even when the overlap is partial, it is meaningful. Yet much of the research ecosystem still treats these diseases as entirely separate challenges.
What Happens When We Work Together?
If diseases overlap, then research should too. Last week at the 2026 Alzheimer’s Disease/Parkinson’s Disease Conference, researchers from around the world came together to share their latest developments, with the clearest messaging being that these two diseases have more in common than once thought.
This type of collaboration and communication across disciplines and disease areas, creates three major advantages:
- Faster discovery: insights in one disease can accelerate breakthroughs in another. A target identified in FTD may have implications for Alzheimer’s disease and vice versa.
- Smarter use of resources: shared datasets, lab equipment, and clinical findings reduce duplication and increase efficiency.
- Stronger innovation: when researchers challenge each other’s assumptions across fields, new ideas emerge—often where disciplines intersect.
Neurodegenerative diseases are complex, overlapping, and deeply interconnected. Treating them in isolation limits our ability to fully understand and ultimately, develop viable treatments to slow their progression or cure them all together.
A Model in Pittsburgh, Built for This Moment
This is the exact philosophy behind our collaborative research cohort – The CTF Consortium. Rather than funding isolated efforts, the CTF Consortium is the only research initiative in Allegheny County that brings together researchers across all forms of dementia and asks them to do something simple but powerful: Share.
Share findings.
Share tools.
Share lab capabilities.
Share perspectives.
This model does not just fund research - it connects it.
With this type of collaboration, we can accelerate results and maximize donor investment, generating up to three times the impact of traditional research models!
The Path Forward
If we want to accelerate progress, we need to rethink how research is done and:
- Encourage cross-disease collaboration
- Invest in shared research infrastructure
- Break down institutional and funding silos
- Support models like the CTF Consortium
As we continue to grow our ongoing commitment towards impact, strong innovation, and ensuring the most cutting-edge translational research remains supported, the CTF Consortium is currently accepting open RPF applications for consideration of funding through 2026–2027. Interested researchers who meet the qualifications outlined in the RFP guidelines are encouraged to apply.
Learn more and be a part of a movement that is breaking research barriers by fostering collaboration for accelerated results towards a cure https://clearthoughtsfoundation.org/ctf-consortium/.
